Skip to main content

ALMUTH

ALzheimer and MUsic THerapy: effects of music lessons on brain plasticity, mood, and quality of life in Alzheimer patients

Sponsor
University of Bergen
Drug
Neurocognitive music therapy (music lessons)
Countries

Information about the intervention that will be tested in the study

Administration

Singing lessons provided by a person with a qualification in music therapy once a week

Will all participants receive the same intervention?

Participants will be selected at random to either receive one of the following options:

  • Neurocognitive music therapy
  • Physical activity intervention (control group receiving an intervention comparable in scope and extent to the music lessons, but not using music such as mountain hikes)
  • No intervention (control group).

Information about participating in the study

What are the researchers trying to find out?

The purpose of the study is to evaluate the effects of music lessons on brain plasticity, mood and quality of life in people with Alzheimer’s disease.

How long will the study last?

12 months

What your involvement will entail?
  • During the study, participants will have to do brain scans (MRI)
  • Participants will need to complete some tests to evaluate their cognition, behaviour, function, depression, language, activities of daily living (e.g. GDS, IADL, MMSE).

Further information on the procedures, tests and number of visits can be obtained from the study team.

Who can participate in this study?

Who can participate in the study?

To take part in the study, participants must:

  • Be 18 years old and older
  • Have a diagnosis of Alzheimer’s disease
  • Live independently at home (not in a care home or similar aged care facility)
  • Be able to complete questionnaires in Norwegian
  • Be able to undergo brain scans (MRI)
  • Be able to come in the area of Bergen (Norway) to attend interventions and assessments.
Who cannot participate in the study?

People cannot take part in the study if they have:

  • Hearing impairment that cannot be mended by hearing aids
  • Any contraindication to brain scans (i.e. claustrophobia, metal objects in body such as pacemaker).

The above list is not exhaustive. It includes the most common conditions and diseases that might exclude people from the study.

Information for your doctor

Clinicaltrials.gov identifier

NCT03444181

Study contact information

Stefan Koelsch +47 55 58 62 31 stefan.koelsch@uib.no

Birthe K Flo +47 55 58 62 09 Birthe.Flo@uib.no

Link to full text

https://clinicaltrials.gov/ct2/show/NCT03444181

The information contained in this document is based on information available on public registries (e.g. clinicaltrials.gov website) on January 2023.

This document has been reviewed by the institution running this trial.

 
Acknowledgement

Alzheimer Europe's Clinical Trials Watch database was developed as part of the 2018 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).

Alzheimer Europe gratefully acknowledges the support of its corporate sponsors for the update and maintenance of the database.

Image
ctw_acknowledgment_2023